echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Newest! Kelun pharmaceutical announced the development progress of four new anti viral drugs

    Newest! Kelun pharmaceutical announced the development progress of four new anti viral drugs

    • Last Update: 2020-02-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On February 17, Sichuan Kelun Pharmaceutical Co., Ltd issued an enterprise announcement Since its subsidiary Sichuan Kelun Pharmaceutical Research Institute Co., Ltd set up a research team of anti new viral drugs on January 21, it has made every effort to promote the research of one innovative peptide drug and three generic drugs covering the prevention and treatment effects Now it is announced the development of four drugs Novel coronavirus (1.): the development background: to design a new polypeptide that specifically targets the viral S protein and the host cell surface receptor ACE2, and blocks the adsorption and fusion of virus and cells, so as to prevent the new virus infection 2 Research progress: Kelun pharmaceutical has completed the design and synthesis of 20 polypeptides by using the existing computer-aided design, polypeptide drug research ability and inhalation preparation research and development platform; through in vitro activity screening and primate safety evaluation, four polypeptide candidate molecules with good biological activity and safety have been obtained; one polypeptide has completed the scale-up production and obtained We need to enlarge the sample of the preparation; at present, we are trying our best to promote the follow-up research, including the human safety test, in order to provide effective preventive drugs for the front-line medical staff, the government's epidemic prevention agencies, and the grass-roots high-risk staff as soon as possible (two) novel coronavirus novel coronavirus (1.) is the first to fifth edition of the new pneumonia diagnostic protocol for coronavirus infection Ritonavir Tablets is recommended for the treatment of new coronavirus infection The 1 is the new version of the virus Taking advantage of the technical advantages in the field of hot melt extrusion platform, Kelun pharmaceutical has completed the research and development of formulation process of lopinavir / ritonavir 2 tablets, and entered into the trial production stage of production line standardization It is expected to realize the mass production of this product in early March; when necessary, it can quickly donate to epidemic areas The novel coronavirus capsule is the first line of treatment for influenza vaccine recommended by the Health Council 2 new cases of coronavirus infection have been confirmed by combination of oseltamivir and ritonavir / ritonavir At present, Kelun pharmaceutical has passed human bioequivalence research and has many batches of mass production samples, which can quickly donate to epidemic areas when necessary In addition, Kelun Pharmaceutical Co., Ltd has successfully copied and developed a drug substance against new coronavirus by taking advantage of its technical advantages in the development of complex APIs and injections, and the formulation process has been determined in the preparation research; it is expected that the mass production capacity of the generic drug will be realized in the middle of March; when necessary, it can quickly donate to epidemic areas 37
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.